Resistance to antiretroviral drugs
Rosina, M.
Recenti Progressi in Medicina 92(9): 546-551
2001
ISSN/ISBN: 0034-1193 PMID: 11552315 Document Number: 528568
Since the HIV eradication is an utopian goal the only hope we have is the appropriate follow up of the disease by maintaining the RNA viral load under control and the level of CD4+ sufficient for a minimum of immunocompetence guarantee. The international guideline for the management of HIV infected patients, annually updated, recently confirmed the importance of the GART (guided antiretroviral therapy) based on information derived from drug resistance laboratory tests. A general survey on the antiretroviral drugs, on the mutations involving drug resistance and on the tests for their detection could be interesting also for whom not specifically working on the field.
Document emailed within 1 workday
Related Documents
Calvez, V. 1998: Resistance to antiretroviral drugs Antiviral Therapy 3 Suppl. 4: 5-7Gómez-Cano, M.; Soriano, V. 1997: Resistance to antiretroviral drugs Medicina Clinica 109(14): 546-548
Hamers, R.L.; Derdelinckx, I.; van Vugt, M.èl.; Stevens, W.; Rinke de Wit, T.F.; Schuurman, R. 2008: The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa Antiviral Therapy 13(5): 625-639
Hamers, R.L.; Derdelinckx, I.; van Vugt, M.èl.; Stevens, W.; Rinke de Wit, T.F.; Schuurman, R. 2008: The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa Antiviral Therapy 13(5): 625-639
Vergne, L.; Malonga-Mouellet, G.; Mistoul, I.; Mavoungou, R.; Mansaray, H.; Peeters, M.; Delaporte, E. 2002: Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries Journal of Acquired Immune Deficiency Syndromes 29(2): 165-168
Vergne, L.; Malonga-Mouellet, G.; Mistoul, I.; Mavoungou, R.; Mansaray, H.; Peeters, M.; Delaporte, E. 2002: Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries Journal of Acquired Immune Deficiency Syndromes 29(2): 165-168
Zapiola, I.és.; Cecchini, D.; Fernández Giuliano, S.; Martínez, M.; Rodríguez, C.; Bouzas, M.ía.B.én. 2016: HIV-1 resistance to antiretroviral drugs in pregnant women from Buenos Aires metropolitan area Medicina 76(6): 349-354
Castelbranco, E.P.íc.A.é F.él.; da Silva Souza, E.; Cavalcanti, A.M.S.; Martins, A.él.N.; de Alencar, L.C.úd.A.; Tanuri, A. 2010: Frequency of primary resistance to antiretroviral drugs and genetic variability of HIV-1 among infected pregnant women recently diagnosed in Luanda-Angola Aids Research and Human Retroviruses 26(12): 1313-1316
Gupta, R.K.; Wainberg, M.A.; Brun-Vezinet, F.; Gatell, J.M.; Albert, J.; Sönnerborg, A.; Nachega, J.B. 2013: Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs Journal of Infectious Diseases 207 Suppl. 2: S101-S106
Muhamadi, L.; Nsabagasani, X.; Tumwesigye, M.Nazarius.; Wabwire-Mangen, F.; Ekström, A-Mia.; Peterson, S.; Pariyo, G. 2010: Inadequate pre-antiretroviral care, stock-out of antiretroviral drugs and stigma: policy challenges/bottlenecks to the new WHO recommendations for earlier initiation of antiretroviral therapy (CD<350 cells/microL) in eastern Uganda Health Policy 97(2-3): 187-194
Baesi, K.; Ravanshad, M.; Ghanbarisafari, M.; Saberfar, E.; Seyedalinaghi, S.; Volk, J.E. 2014: Antiretroviral drug resistance among antiretroviral-naïve and treatment experienced patients infected with HIV in Iran Journal of Medical Virology 86(7): 1093-1098
Corzillius, M.; Mühlberger, N.; Sroczynski, G.; Jaeger, H.; Wasem, J.ür.; Siebert, U. 2004: Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV Antiviral Therapy 9(1): 27-36
Hamers, R.L.; Wallis, C.L.; Kityo, C.; Siwale, M.; Mandaliya, K.; Conradie, F.; Botes, M.E.; Wellington, M.; Osibogun, A.; Sigaloff, K.C.E.; Nankya, I.; Schuurman, R.; Wit, F.W.; Stevens, W.S.; van Vugt, Mèle.; de Wit, T.F.Rinke.; Mandaliya, K.; Abdallah, S.; Jao, I.; Dolan, M.; Schuurman, R.; Wensing, A.M.; Hamers, R.L.; Sigaloff, K.C.E.; Straatsma, E.; Wit, F.W.; van Vugt, M.; Lange, J.M.; Rinke de Wit, T.F.; Osibogun, A.; Akanmu, S.; Botes, M.E.; Conradie, F.; Ive, P.; Sanne, I.; Wallis, C.L.; Letsoalo, E.; Stevens, W.S.; Hardman, M.; Kityo, C.; Namayanja, G.; Nakatudde, L.; Nankya, I.; Kiconco, M.; Abwola, M.; Mugyenyi, P.; Ndembi, N.; Lyagoba, F.; Kaleebu 2011: HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study Lancet. Infectious Diseases 11(10): 750-759
Diouf, A.; Youbong, T.J.; Maynart, M.; Ndoye, M.; Diéye, F.L.; Ndiaye, N.A.; Koita-Fall, M.B.; Ndiaye, B.; Seydi, M. 2017: Non-antiretroviral drugs uses among HIV-infected persons receiving antiretroviral therapy in Senegal: Costs and factors associated with prescription Revue d'Epidemiologie et de Sante Publique 65(4): 295-300
Newman, H.; Breunig, L.; van Zyl, G.; Stich, A.; Preiser, W. 2014: A qualitative PCR minipool strategy to screen for virologic failure and antiretroviral drug resistance in South African patients on first-line antiretroviral therapy Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology 60(4): 387-391
Wendo, C. 2003: Africans advocate antiretroviral strategy similar to DOTS. AIDS experts suggest community health workers should help in the delivery of antiretroviral drugs Lancet 362(9391): 1210
Baba, H. 1994: Studies on the problems of resistance to antituberculous drugs. II--1. Clinically applicable criteria of drug-resistance to rifampicin Kekkaku: 69(6): 387-396
Hamers, R.L.; Schuurman, R.; Sigaloff, K.C.E.; Wallis, C.L.; Kityo, C.; Siwale, M.; Mandaliya, K.; Ive, P.; Botes, M.E.; Wellington, M.; Osibogun, A.; Wit, F.W.; van Vugt, M.èl.; Stevens, W.S.; de Wit, T.F.R. 2012: Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study LANCET. Infectious Diseases 12(4): 307-317
Idemyor, V. 2001: HIV resistance and tolerability issues in antiretroviral therapy Journal of the National Medical Association 93(4): 151-153
Richman, D.D. 2012: Antiretroviral drug resistance in resource-limited settings Lancet 380(9849): 1210-1211